Work

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404

Year: 2017

Type: article

Study design: Clinical Trial

Source: Lung Cancer

DOI: 10.1016/j.lungcan.2017.11.025

Authors: Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, Daijiro Harada, Toshio Kubo, Kadoaki Ohashi, Shoichi Kuyama, Kenichiro Kudo, Akihiro Bessho, Nobuaki Fukamatsu, Nobukazu Fujimoto, Keisuke Aoe, Takuo Shibayama, Keisuke Sugimoto, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura

Institutions: Okayama University, Okayama University Hospital, Shikoku Cancer Center, Iwakuni Medical Center, Okayama Red Cross General Hospital, Okayama Rosai Hospital, National Sanyo Hospital, National Hospital Organization, Okayama Medical Center, Japanese Red Cross Kobe Hospital, Kawasaki Medical School

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Center for Innovative Clinical Medicine, Okayama University Hospital, AstraZeneca, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Japan Society for the Promotion of Science

Awards: Development of a novel therapeutic strategy for lung cancer with interstitial pneumonia - from the viewpoint of chemoprevention -, Next generation lung cancer mice model for conquering cancer stem, Comprehensive analysis of druggable tyrosine kinase in idiopathic interstitial pneumonia

OpenAlex ID: W2770832207

FWCI: 2.439

Cites: 16

Cited by: 25

Related to: 10